Bayer New Zealand Limited

Other

Bayer Intellectual Property Gmbh

Fadil Al Alawi

Karthigeyan Nanjan

Olaf Bork

Wayne Frederick Leech

Ian George Tucker

Paul Chambers

Kate Hill

Rohit Jain

Man Yik Li

Steve Li

The present invention relates to a composition, the composition including a therapeutically effective amount of at least one active agent, and a base including, an amount of colloidal silica; at least one oil; and at least one surfactant, wherein the viscosity of the composition is below 1000 mPas at a shear rate of 100 l/s and at a temperature of 20&#xb0; C.

Controlled release compositions and their methods of use

This invention relates to a composition, including penethamate (PNT) or a pharmaceutical equivalent thereof; and at least one oily vehicle.

Injectable antibiotic formulations and their methods of use

The present invention relates to a long-acting composition for the treatment of an animal in need thereof wherein the composition includes a therapeutically effective amount of a bioactive agent, characterized in that the composition includes a non-aqueous carrier and a solvent system comprising castor oil and at least one cyclic amide.

Long acting compositions

This invention relates to a composition, including penethamate (PNT) or a pharmaceutical equivalent thereof; and triacetin.

This invention relates to a veterinary antiparasitic solubilized composition including a macrocyclic lactone or a pharmaceutically equivalent salt thereof, and levamisole or a pharmaceutically equivalent salt thereof, characterized in that the pH of the composition is in the range of 2.0 to 5.0 and wherein the composition includes at least one surfactant and at least one antioxidant.

Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation

The invention relates to a table formulated for administration to an animal to treat parasite infestation. The tablet includes at least one macrocyclic lactone compound with anthelmintic activity dissolved in at least one organic solvent and subsequently formulated into a tablet. The tablets produced have a high degree of stability when stored over time and also provide the animal with a dose of agent sufficient to be therapeutically effective.

Macrocyclic lactone tablet formulation

The invention relates to composition and related therapeutic methods including at least one antihyperthyroid drug formulated for transdermal administration. Because the formulation is formulated for transdermal administration, the formulation is easier to administer than existing formulations which are administered orally to animals. Issues surrounding transdermal administration versus oral administration have also been resolved allowing the agent to remain stable during storage and retain a high level of efficacy.

Growing community of inventors

Auckland, New Zealand

Fadil Al Alawi